FDA Accepts Opicapone NDA for Adjunctive Treatment of Parkinson Disease

FDA Accepts Opicapone NDA for Adjunctive Treatment of Parkinson Disease
Neurocrine Biosciences announced that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for opicapone, an investigational once daily selective catechol-O-methyltransferase (COMT) inhibitor, for adjunctive treatment to levodopa/carbidopa in patients with Parkinson disease experiencing OFF episodes. Opicapone works by decreasing the conversion rate of levodopa into 3-O-methyldopa thus prolonging the clinical effects and availability of levodopa ... read more
Source: Neurology AdvisorPublished on 2019-07-15By Jennifer Mannheim